CI & Patents (Pharma) News: 15/02/2011


1) Apricus Biosciences and Neopharm Group Sign Licensing Agreement for Vitaros (alprostadil) in Israel for up to $4.35 Million, Plus Royalties (Yahoo finance);

2) The Medicines Company and WilmerHale Law Firm Reach Settlement Agreement (Yahoo finance); Under the settlement agreement, The Medicines Company will receive approximately $18 million up front from WilmerHale’s professional liability insurers to cover certain past expenses. An additional $214 million will be available for damages in the event a generic bivalirudin is sold in the United States before June 15, 2015 as a result of the extension of the ‘404 patent being held invalid on the basis that the application for the extension was not timely filed.

3) Malaysia IPO: Patents (Amendment) Regulations 2011 will be effective from the date of 15th Feb 2011 (MYIPO)

4) Antwerp court stops infringement of valsartan/HCTZ SPC based on patent claiming valsartan alone (thespcblog)

5) BioSante Pharmaceuticals Reports Positive LibiGel® Safety Data in Phase III Program (Yahoo finance)

6) Eisai Concludes License Agreement for New Aricept Transdermal Formulation in japan (pharmalive); An adhesive skin patch containing donepezil hydrochloride seems to be protected by WO2007129427.

7) GSK Pharma to launch vaccine, cancer drugs in 2011 (Livemint); “The two oncology drugs, Revolade and Votrient, would be launched by end of first quarter or early second quarter“; The two cancer drugs seem to be protected in India. Revolade (eltrombopag) seems to be protected by 213176 (IN/PCT/2002/1666/MUM) and Votrient (Pazopanib) seems to be protected by210284 (818/KOLNP/2003).

8) Medivir AB Signs Dengue Deal with Johnson & Johnson (Press release)

· Collaboration with Janssen Pharmaceutica N.V. focused on dengue virus

· Both parties to contribute 50:50 resources to the research program

· Strengthens Medivir’s presence in infectious diseases and utilises strong know-how in the discovery of protease inhibitor drugs

9) Obama: Shrink Exclusivity And End Pay-To-Delay (Pharmalot) (WSJ)

10) Venus launches $2 mn super speciality cancer segment (BS)

11) Q-Med settles with Genzyme in US patent dispute (reuters); Genzyme Corporation filed a complaint in the District court of Massachusetts against Medicis alleging that Medicis is infringing on a patent held by Genzyme by marketing Restylane®, Perlane®, Restylane®-L and Perlane®-L in the United States . Now Q-Med said it would make a lump sum payment to Genzyme and Medicis had been released from any liability relating to the lawsuit. (View on RFCexpress); Patent involved: 5,399,351 (assigned to Genzyme Biomatrix)

12) Mylan Launches First Generic Version of Vfend® Tablets (Yahoo finance)

13) Actavis launches Anastrozole on day one in seven major European markets (Press release)

Advertisements

About Guna

Interested to learn things around me
This entry was posted in Daily interesting IP news. Bookmark the permalink.

2 Responses to CI & Patents (Pharma) News: 15/02/2011

  1. Pingback: Pro Blogger News

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s